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sion was made at 14 days after pts completed velafermin adminis-
tration with no dose limiting toxicity reported. All abnormal he-
matology or chemistry laboratory reports were expected and con-
sistent with pt disease conditions. The second cohort of 0.1 mg/kg
dose is ongoing with 2 pts completed study drug infusion. The
safety proﬁle and clinical data of all pts will be reported.
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CAREGIVER SUPPORT GROUP ON PEDIATRIC BONE MARROW TRANS-
PLANT UNIT: WHAT FAMILIES ARE TALKING ABOUT AND WHY THE
MEDICAL TEAM SHOULD LISTEN
Schmid, C.L.1, Calderon, K.S.1, Partin-Welch, P.H.1, Huber, H.1,
Robinson, N.S.1, Van Loon, R.A.2 1. Cincinnati Children’s Hospital
Medical Center, Cincinnati, OH; 2. University of Cincinnati, Cincin-
nati, OH.
Prompted by families’ unrest in the Pediatric Blood and Marrow
Transplant Unit at Cincinnati Children’s Hospital Medical Cen-
ter, in the Spring of 2005, social workers began an hour-long,
weekly support group for caregivers of inpatients. Group atten-
dance has depended upon unit census and other factors such as
caregivers’ ability to leave the child in the room with an attendant.
Notable discussion points have emerged and the group has become
not only a support for caregivers but a guide for the medical team
on how to best assist families and patients through treatment and
recovery. The team’s understanding of the main, or previously
unrecognized, family issues is resulting in a better outcome for the
patients and caregivers. Overt and covert topics have emerged from
the group. Overt topics, or those “on the surface” or “expected” to
appear, remain consistent within almost each discussion. These
explicit topics include difﬁculty with distance from primary resi-
dence and managing the household, beneﬁt in connecting with
other caregivers on the unit, balancing siblings’ needs while caring
for sick child, and ﬁnancial strain. While it is necessary for the
medical team to be mindful of those struggles, it is potentially even
more important to consider covert issues that also make a powerful
impact and often go unnoticed. Covert topics, or those not as
readily voiced but shared among caregivers, may include self-care
and the need to be away from the child to express emotions,
responding to emotionally “needy” families on the unit, physical
impact of illness on the patient, fear of returning to hospital
following discharge, neediness of the ill child, comprehending
medical information and advocating for the child with the medical
team, how to successfully convey concerns to the team, and a
repeated expression in conﬁdence of the medical facility (poten-
tially stated for their own reassurance). In creating a safe environ-
ment for caregivers to share their concerns, struggles, and joys, the
medical team gains a better understanding of how to interpret
caregivers’ behavior and respond within a family-centered care
model. Subsequently, the patient’s treatment and recovery may go
more smoothly with families feeling better supported. Acknowl-
edging the multitude of strains and adjustments that accompany a
prolonged hospitalization will beneﬁt all involved with the pa-
tient’s care and, ultimately, the patient.
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GLUTAMINE SUPPLEMENTATION TO REDUCE ORAL MUCOSITIS IN
MULTIPLE MYELOMA PATIENTS RECEIVING HIGH-DOSE MELPHALAN
AND AUTOLOGOUS STEM CELL TRANSPLANTATION: A FEASIBILITY
STUDY
Hansen, L.K.1, Smythe, P.A.1, Hansen, K.S.1, Gruenberg, D.R.1,
Callaway, D.1 1Legacy Good Samaritan Hospital, NW Marrow Trans-
plant Program, Portland, OR.
Oral mucositis is a common and distressing toxicity associated
with high dose Melphalan (HDM) and autologous stem cell
transplantation (ASCT). The amino acid, glutamine (GLN), has
been employed in an attempt to ameliorate oral mucositis in
various high dose chemotherapy regimens with mixed results.
This pilot study sought to evaluate the feasibility of adminis-
tering an oral GLN food supplement in patients with multiple
myeloma undergoing HDM and ASCT. Twelve patients (3
females and 9 males), median age 51, consented and enrolled in
the trial. GlutaSolve™ (Novartis) 15 gm bid was administered 4
days before the start of HDM and continued for at least 14 days
or 28 doses. Oral assessment and mucositis ratings were scored
by trained oncology nurses and physicians using the NCI Com-
mon Toxicity Criteria, version 3.0. Compliance with bid dosing,
tolerance of GLN, pain medication usage, total parenteral nu-
trition (TPN), and hospital length of stay (LOS) were measured.
The 12 study patients were compared to case controls matched
by gender, age, and presence or absence of renal dysfunction.
Results: The compliance rate for planned GLN doses was 91.3
%. Toxicities were minimal and were limited to occasional
nausea, vomiting, and mild abdominal pain after taking GLN.
Several patients developed aversion to ingesting GLN toward
the end of the treatment period. There were no cases of clinical
grades 3 or 4 oral mucositis observed in the 12 study subjects.
Median clinical mucositis score was grade 1 (mean  1.2) and
median functional mucositis score was grade 1 (mean  1.1).
Control patients had median clinical and functional mucositis
scores of 2 (mean  1.5) and 1 (mean  1.25), respectively. Only
1 study patient developed functional grade 3 mucositis (unable
to adequately aliment or hydrate orally), whereas 3 control
patients experienced grade 3 mucositis. None of the study pa-
tients received TPN and only 1 patient received parenteral
analgesia for oral discomfort. In comparison, 2 controls received
TPN due to oral mucositis and 4 received parenteral analgesia.
Average LOS was 16.8 days for study patients and 17.4 days for
controls. Conclusions: Oral GlutaSolve™ supplement is safe
and well tolerated in patients receiving HDM and ASCT for
treatment of multiple myeloma. Results of this pilot study sug-
gest this inexpensive form of GLN may reduce the severity of
oral mucositis and further study is warranted in patients receiv-
ing HDM and ASCT.
415
ANTIBACTERIAL PROPHYLAXIS DURING NEUTROPENIC PHASE IN AU-
TOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANT (APBSCT).
COMPARISON BETWEEN CIPROFLOXACIN  AMOXICILIN VS. LEVO-
FLOXACIN
Karduss, A.J.1, Gomez, L.R.1, Reyes, P.A.1, Jimenez, J.A.1,
Jaimes, F.2, Deossa, H.1 1. Instituto de Cancerologia - Clinica las
Americas, Medellin, Colombia; 2. Departamento de Medicina Interna -
Universidad de Antioquia, Medellin, Colombia.
From November 2002 to May 2004, the patients who received an
APBST had a prophylactic antibacterial regimen with ciproﬂoxacin
500 mg PO BID  amoxicilin 500 mg PO TID (group A). After
June 2004 our protocol changed to levaquin 500 mg PO daily
(group B). We compared the incidence of fever, infections, and
mortality related to the infections in these 2 groups. All the pa-
tients were in an individual room and they received ﬁlgrastin from
day 7 until neutrophils recovery. In case of fever a complete
physical exam, blood and urine cultures, and chest X-Ray were
done, and a Carbapenem was started. There were 20 patients in
group A, 13 men and 7 women, median age 38.90 years (15–67); 6
HD, 7 MM, 7 NHL. The average time with neutrophils 500 was
9.4 days and for engraftment was 11.4 days. Sixteen of twenty had
fever (80%), in 7 (43.7%) the cause was unknown, in 5 (31.2%) a
bacteria was found (E. coli [3], S. epidermidis[2]); 1 patient had
pneumonia caused by A. fumigatus, and 3 had engraftment syn-
drome and there were no deaths. Group B were 19 patients, 12
men and 7 women, median age 50.5 (24–60), 10 MM, 5 NHL, 4
HD. Average time with neutrophils500 was 9.47 days (7–12) and
for engraftment was 11.42 days (11–14). Seventeen patients had
fever (89.4%): 12 (70%) of unknown cause, in 3 (17.6%) a bacteria
was found (Burkhordelia cepacea [1], E. coli [2]), 1 had engraftment
syndrome and 1 pneumonia without germ. We had no deaths due
to infection, and 1 patient died secondary to VOD. For comparing
the groups a Fisher’s test was done, and there were no signiﬁcant
differences in frequency of fever cases (P  .365) nor bacteremia
cases (P  .378). These results remained non signiﬁcant after
adjustment with a logistic model for neutropenia days and the
average of days for engraftment between the groups; Wald test for
fever P .578 and for bacteremia, P .370. The prophylaxis daily
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